|
1.
|
|
9 p, 850.8 KB |
Intermittent hypoxia is associated with high hypoxia inducible factor-1α but not high vascular endothelial growth factor cell expression in tumors of cutaneous melanoma patients
/
Almendros, Isaac (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez-García, Miguel Ángel (Hospital Universitari i Politècnic La Fe (València)) ;
Campos-Rodríguez, Francisco (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Riveiro-Falkenbach, Erica (Hospital Universitario 12 de Octubre) ;
Rodríguez-Peralto, José L. (Hospital Universitario 12 de Octubre) ;
Nagore, Eduardo (Fundació Institut Valencià d'Oncologia) ;
Martorell-Calatayud, Antonio (Hospital de Manises (València)) ;
Blasco, Luis Hernández (Univ. Miguel Hernandez) ;
Roca, Jose Bañuls (Univ. Miguel Hernandez) ;
Vives, Eusebi Chiner (Hospital san Juan de Alicante) ;
Sánchez-de-la-Torre, Alicia (Hospital Universitari Arnau de Vilanova i Santa Maria) ;
Abad Capa, Jorge (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Montserrat Canal, José Ma (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Gil, Amalia (Hospital de Valme) ;
Cabriada-Nuño, Valentín (Hospital Universitario Cruces) ;
Cano-Pumarega, Irene (Hospital Universitario de Getafe) ;
Corral-Peñafiel, Jaime (Hospital Universitario S. Pedro Alcántara) ;
Diaz-Cambriles, Trinidad (Hospital 12 de Octubre (Madrid)) ;
Mediano, Olga (CIBER de enfermedades respiratorias) ;
Dalmau-Arias, Joan (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Farré, Ramón (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gozal, David (The University of Chicago) ;
Herrera, Elidia Molina (Hospital 12 de Octubre (Madrid)) ;
García Martín, Rosa M. (Hospital 12 de Octubre (Madrid)) ;
de Jaime, Maria Niveiro (Universidad Miguel Hernandez) ;
Moreno, Sara (Hospital Universitario Arnau de Vilanova) ;
Ilia, Ferran Barbé (Hospital Universitari Arnau de Vilanova i Santa Maria) ;
de la Torre, Manuel Sánchez (Hospital Universitari Arnau de Vilanova i Santa Maria) ;
de Eusebio, Esther (Hospital Universitario de Guadalajara) ;
Landete, Pedro (Instituto de Investigación Hospital Universitario de la Princesa) ;
Gordon, Manuel Moragón (Hospital Universitario) ;
Arias, Eva (Hospital 12 de Octubre (Madrid)) ;
Masa, Fernando (Hospital Universitario S. Pedro Alcántara) ;
Herrada, Carlos González (Hospital Universitario de Getafe) ;
Carrera, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Muñoz Ferrer, Aida (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fortuna Gutiérrez, Ana Mª (Institut d'Investigació Biomèdica Sant Pau) ;
Mayos, Mercè (Institut d'Investigació Biomèdica Sant Pau) ;
García, Jesús Gardeazabal (Hospital Universitario Cruces) ;
Universitat Autònoma de Barcelona
Epidemiological associations linking between obstructive sleep apnea and poorer solid malignant tumor outcomes have recently emerged. Putative pathways proposed to explain that these associations have included enhanced hypoxia inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) cell expression in the tumor and altered immune functions via intermittent hypoxia (IH). [...]
2018 -  10.3389/fneur.2018.00272
Frontiers in neurology, Vol. 9 Núm. APR (26 2018) , p. 272
|
|
|
2.
|
|
14 p, 1.0 MB |
Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma : A Multicenter Propensity Score Matching Study
/
Tejera-Vaquerizo, Antonio (Hospital San Juan de Dios) ;
Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ribero, Simone (University of Turin) ;
Puig, Susana (Hospital Clínic i Provincial de Barcelona) ;
Paradela, Sabela (Hospital Universitario de la Coruña) ;
Moreno-Ramírez, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Cañueto, Javier (Complejo Asistencial Universitario de Salamanca) ;
de Unamuno-Bustos, Blanca (Hospital Universitari i Politècnic La Fe (València)) ;
Brinca, Ana (University Hospital of Coimbra) ;
Descalzo-Gallego, Miguel A. (Fundación Piel Sana) ;
Osella-Abate, Simona (University of Turin) ;
Cassoni, Paola (University of Turin) ;
Podlipnik, Sebastian (Hospital Clínic i Provincial de Barcelona) ;
Carrera, Cristina (Hospital Clínic i Provincial de Barcelona) ;
Vidal-Sicart, Sergi (Hospital Clínic i Provincial de Barcelona) ;
Pigem, Ramón (Hospital Clínic i Provincial de Barcelona) ;
Toll Abelló, Agustí (Hospital Clínic i Provincial de Barcelona) ;
Rull, Ramón (Hospital Clínic i Provincial de Barcelona) ;
Alos, Llucìa (Hospital Clínic i Provincial de Barcelona) ;
Requena, Celia (Fundació Institut Valencià d'Oncologia) ;
Bolumar, Isidro (Fundació Institut Valencià d'Oncologia) ;
Traves, Víctor (Fundació Institut Valencià d'Oncologia) ;
Pla, Ángel (Fundació Institut Valencià d'Oncologia) ;
Fernández-Orland, Almudena (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Jaka, Ane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernandez Figueras, Maria Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Richarz, Nina Anika (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vieira, Ricardo (University Hospital of Coimbra) ;
Botella-Estrada, Rafael (Hospital Universitari i Politècnic La Fe (València)) ;
Román-Curto, Concepción (Complejo Asistencial Universitario de Salamanca) ;
Ferrándiz-Pulido, Lara (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Iglesias-Pena, Nicolás (Hospital Universitario de la Coruña) ;
Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Malvehy, Josep (Hospital Clínic i Provincial de Barcelona) ;
Quaglino, Pietro (University of Turin) ;
Nagore, Eduardo (Fundació Institut Valencià d'Oncologia) ;
Universitat Autònoma de Barcelona
The therapeutic value of sentinel lymph node biopsy (SLNB) in thin melanoma remains controversial. The aim of this study is to determine the role of SLNB in the survival of thin melanomas (≤1 mm). [...]
2021 - 10.3390/jcm10245878
Journal of clinical medicine, Vol. 10 (december 2021)
|
|
|
3.
|
|
|
4.
|
|
18 p, 8.9 MB |
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
/
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ;
González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Vall d'Hebron Institut d'Oncologia) ;
Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Nonell, Lara (Vall d'Hebron Institut d'Oncologia) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. [...]
2023 - 10.1101/gad.350078.122
Genes & Development, Vol. 37 (april 2023) , p. 303-320
|
|
|
5.
|
|
11 p, 3.4 MB |
PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
/
Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ;
Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ;
Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ;
Boland, Genevieve (Massachusetts General Hospital (Boston)) ;
Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ;
Lewis, Karl D. (University of Colorado Cancer Center) ;
Johnson, Daniel (Ochsner Medical Center) ;
Rivalland, Gareth (University of Auckland & Auckland City Hospital) ;
Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Gogas, Helen (National & Kapodistrian University of Athens) ;
Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ;
Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ;
Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913
|
|
|
6.
|
|
|
7.
|
|
19 p, 964.7 KB |
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness
/
Carrier, Arnaud (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Desjobert, Cécile (Unité de Service et de Recherche) ;
Ponger, Loic (Sorbone University) ;
Lamant, Laurence (Université Toulouse III Paul Sabatier) ;
Bustos, Matias (Saint John's Cancer Institute) ;
Torres Ferreira, Jorge (Portuguese Oncology Institute of Porto) ;
Henrique, Rui (University of Porto) ;
Jeronimo, Carmen (University of Porto) ;
Lanfrancone, Luisa (Instituto Europeo di Oncologia) ;
Delmas, Audrey (Université Toulouse III Paul Sabatier) ;
Favre, Gilles (Université Toulouse III Paul Sabatier) ;
Daunay, Antoine (Fondation Jean Dausset-CEPH) ;
Busato, Florence (Université Paris-Saclay. Centre National de Recherche en Génomique Humaine) ;
Hoon, Dave S. B. (Saint John's Cancer Institute) ;
Tost, Jorg (Université Paris-Saclay. Centre National de Recherche en Génomique Humaine) ;
Etievant, Chantal (Unité de Service et de Recherche) ;
Riond, Joëlle (Université Toulouse III Paul Sabatier) ;
Arimondo, Paola Barbara (Institut Pasteur)
Aberrant DNA methylation is a well-known feature of tumours and has been associated with metastatic melanoma. However, since melanoma cells are highly heterogeneous, it has been challenging to use affected genes to predict tumour aggressiveness, metastatic evolution, and patients' outcomes. [...]
2022 - 10.7554/eLife.78587
eLife, Vol. 11 (september 2022) , p. e78587
|
|
|
8.
|
|
13 p, 822.1 KB |
SEOM clinical guideline for the management of cutaneous melanoma (2020)
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Manzano, J. L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Marquez-Rodas, I. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Mujika, K. (Department of Medical Oncology. UGC de Oncología de Gipuzkoa. OSI Donostialdea-Onkologikoa) ;
Muñoz-Couselo, E. (Vall d'Hebron Institut d'Oncologia) ;
Pérez-Ruiz, E. (Instituto de Investigación Biomédica de Málaga) ;
de la Cruz Merino, Luis (Universidad de Sevilla) ;
Espinosa, E. (Hospital Universitario La Paz (Madrid)) ;
Gonzalez-Cao, M. (Oncology Department (IOR). Hospital Dexeus) ;
Berrocal, A. (Department of Medical Oncology. Consorcio Hospital General Universitario de Valencia)
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. [...]
2021 - 10.1007/s12094-020-02539-9
Clinical & Translational Oncology, Vol. 23 Núm. 5 (may 2021) , p. 948-960
|
|
|
9.
|
|
24 p, 4.6 MB |
Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach
/
Dublang, Leire (Universidad del País Vasco. Departamento de Bioquímica y Biología Molecular) ;
Underhaug, Jarl (University of Bergen. Department of Chemistry) ;
Flydal, Marte I. (University of Bergen. Department of Biomedicine) ;
Velasco-Carneros, Lorea (Universidad del País Vasco. Departamento de Bioquímica y Biología Molecular) ;
Maréchal, Jean-Didier (Universitat Autònoma de Barcelona. Departament de Química) ;
Moro, Fernando (Universidad del País Vasco. Departamento de Bioquímica y Biología Molecular) ;
Boyano, Maria Dolores (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Martinez, Aurora (University of Bergen. Department of Biomedicine) ;
Muga, Arturo (Universidad del País Vasco. Departamento de Bioquímica y Biología Molecular)
High levels of Heat shock proteins (Hsps) in specific cancers are usually linked to a poor prognosis, tumor progression, invasiveness, and resistance to treatment. Chaperone inhibition could therefore be toxic for cancer cells due to their high dependence on chaperone activity to survive. [...]
2021 - 10.3390/cancers13122936
Cancers, Vol. 13, Issue 12 (June 2021) , art. 2936
|
|
|
10.
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
